Suivre
Abonner SemBioSys, Genetics Inc

SemBioSys, Genetics Inc

Filtre
  • 29.07.2008 – 13:06

    SemBioSys Submits IND for Safflower-Produced Insulin to U.S. FDA

    Calgary (ots/PRNewswire) - - Submission Demonstrates Progress of Plant-Derived Insulin Program Scheduled to Enter the Clinic Later This Year SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has submitted an Investigational New Drug ...

  • 05.06.2008 – 13:03

    SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)

    Calgary, Canada (ots/PRNewswire) - - Company Achieves Important Milestone in Development of Next Generation Cardiovascular Drug SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company dedicated to developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has demonstrated that its safflower-produced ...

  • 30.04.2008 – 13:05

    Botaneco Signs Feasibility Agreement With Croda to Develop Specialty Crop Oil Formulation

    Calgary, Canada (ots/PRNewswire) - - Program Will Focus on Evaluation of Botaneco's Technology to add Functionality to Echium oil Botaneco, a wholly-owned subsidiary of SemBioSys Genetics Inc., today announced that it has signed a feasibility agreement with Croda Enterprise Technology, part of Croda International Plc, an international manufacturer of ...

  • 26.03.2008 – 12:07

    SemBioSys Initiates Toxicology Study for Safflower-Produced Insulin

    Calgary, Canada (ots/PRNewswire) - - Initiation of Study Puts Company on Track for Phase I/II Trial SemBioSys Genetics Inc. (TSX: SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today announced that it has initiated a toxicology study in animals to demonstrate the safety ...

  • 18.10.2007 – 17:51

    SemBioSys Confirms Commercially Viable Levels of Native APO AI in Safflower

    Calgary, Canada (ots/PRNewswire) - - Canadian Biotechnology Company has now Established Commercial Levels of Both Native Apo AI and Apo AI(Milano) variant in Safflower Seed Lines SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases , today announced that it has ...

  • 22.08.2007 – 13:06

    SemBioSys Updates Apo AI Development Program

    Calgary, Canada (ots/PRNewswire) - - Canadian Biotechnology Company Confirms Commercial Expression Levels of Apo AI Milano Variant and Clarifies Status of Native Apo AI SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular diseases, today updated a release issued on July 12, 2007 announcing that the Company had achieved ...

  • 12.07.2007 – 13:10

    SemBioSys Achieves Critical Apo AI Milestone

    Calgary, Canada (ots/PRNewswire) - - Canadian Biotechnology Company is the First Company in the World to Produce Recombinant Apo AI, a Next Generation Cardiovascular Therapy, Using Plants SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company, today announced it has successfully developed commercial levels of apolipoprotein AI and its variant apolipoprotein AI(Milano) (collectively referred to as Apo AI) ...

  • 26.06.2007 – 14:23

    SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference

    Calgary, Canada (ots/PRNewswire) - - Canadian Biotechnology Company Updates Progress and Upcoming Milestones on its Insulin Program - TSX symbol: SBS SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing a portfolio of therapeutic proteins for metabolic and cardiovascular disease, today announced positive preclinical data supporting the ...

  • 03.05.2007 – 20:05

    /C O R R E C T I O N -- SemBioSys Genetics Inc./

    Calgary , Canada (ots/PRNewswire) - In the news release, "SemBioSys Announces First Quarter Results" issued on 3 May 2007 11:00 GMT, by SemBioSys Genetics Inc. TSX:SBS over PR Newswire, we are advised by a representative of the company that errors occurred in the headings of the financial tables. The comparative years were transposed by CNW in error. Complete corrected copy follows: - SemBioSys Announces First ...

  • 03.05.2007 – 13:05

    SemBioSys Announces First Quarter Results

    Calgary , Canada (ots/PRNewswire) - - Canadian Biotechnology Company Achieves Insulin Milestones and Strengthens Balance Sheet SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing insulin and other metabolic and cardiovascular protein-based pharmaceuticals and a series of non-pharmaceutical products, today announced its operational and financial results for the 2007 first quarter which ...